Tests PF-08046876, a new drug, in adults with advanced solid tumors
Tests a new antibody drug in adults with advanced bladder or lung cancer.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Key facts
- Where
- Barcelona and Madrid, SpainSee the 3 sites
- Phase
- Phase 1
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07090499EU 2025-521729-33-00
- Record updated
- 5 November 2026
- Original description
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them.Read full original descriptionShow less
A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them.
The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules. In the second part of the study, groups of people will receive the study drug in dosing regimens deemed to be safe in Part 1. In the third part of the study, people will receive the study drug together with other anti-cancer medicines.
Inclusion: 18 years of age or older; Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas; Measurable disease; ECOG Performance status 0-1; Part 1: progression or relapse following standard treatments; Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting; Part 3: advanced cancer of the lung or bladder, prior treatment requirements vary by combination therapy group; Resolution of acute effects of prior anticancer therapy to baseline or Grade 1; Consent to submit required pre-treatment tumor tissue as medically feasible.
Exclusion: Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan ); Pulmonary disease meeting protocol exclusion; Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion; Other unacceptable abnormalities as defined by protocol; Part 3: Meet contraindications of combination products per protocol and/or local labels.